Sanibel Captiva Trust Company Inc. Sells 2,850 Shares of Aflac Incorporated (NYSE:AFL)

Sanibel Captiva Trust Company Inc. cut its stake in Aflac Incorporated (NYSE:AFL) by 18.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,264 shares of the financial services provider’s stock after selling 2,850 shares during the quarter. Sanibel Captiva Trust Company Inc.’s holdings in Aflac were worth $1,364,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in AFL. Whipplewood Advisors LLC purchased a new position in Aflac in the fourth quarter valued at about $26,000. BankPlus Trust Department purchased a new stake in shares of Aflac during the fourth quarter valued at about $34,000. Curio Wealth LLC bought a new stake in shares of Aflac in the 4th quarter valued at about $36,000. Capital A Wealth Management LLC bought a new stake in shares of Aflac in the 4th quarter valued at about $38,000. Finally, OFI Invest Asset Management purchased a new position in shares of Aflac in the 4th quarter worth approximately $38,000. 67.44% of the stock is owned by institutional investors.

Aflac Trading Down 0.3%

Shares of NYSE:AFL opened at $102.23 on Wednesday. The company has a quick ratio of 0.08, a current ratio of 0.10 and a debt-to-equity ratio of 0.29. Aflac Incorporated has a 52-week low of $86.46 and a 52-week high of $115.50. The stock has a market cap of $55.27 billion, a price-to-earnings ratio of 10.65, a PEG ratio of 3.24 and a beta of 0.82. The business has a 50-day moving average price of $105.00 and a 200-day moving average price of $105.78.

Aflac (NYSE:AFL) last posted its quarterly earnings results on Wednesday, April 30th. The financial services provider reported $1.66 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.67 by ($0.01). Aflac had a return on equity of 16.20% and a net margin of 28.76%. The business had revenue of $3.40 billion for the quarter, compared to analysts’ expectations of $4.53 billion. During the same period in the prior year, the business posted $1.66 earnings per share. The business’s quarterly revenue was down 37.5% compared to the same quarter last year. Equities analysts predict that Aflac Incorporated will post 6.88 EPS for the current year.

Aflac Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Wednesday, May 21st were issued a dividend of $0.58 per share. The ex-dividend date was Wednesday, May 21st. This represents a $2.32 annualized dividend and a dividend yield of 2.27%. Aflac’s dividend payout ratio (DPR) is presently 36.25%.

Insider Activity at Aflac

In other Aflac news, Director Masatoshi Koide sold 37,000 shares of Aflac stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $105.59, for a total value of $3,906,830.00. Following the completion of the transaction, the director now owns 70,992 shares of the company’s stock, valued at approximately $7,496,045.28. The trade was a 34.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Joseph L. Moskowitz sold 1,000 shares of the company’s stock in a transaction dated Thursday, May 8th. The stock was sold at an average price of $106.79, for a total transaction of $106,790.00. Following the completion of the transaction, the director now owns 26,096 shares of the company’s stock, valued at approximately $2,786,791.84. This trade represents a 3.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold 40,750 shares of company stock worth $4,304,295 over the last three months. Company insiders own 0.90% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. UBS Group increased their target price on shares of Aflac from $109.00 to $114.00 and gave the company a “neutral” rating in a research report on Wednesday, April 2nd. Keefe, Bruyette & Woods increased their price objective on Aflac from $104.00 to $106.00 and gave the company a “market perform” rating in a report on Wednesday, May 7th. Wells Fargo & Company raised their price objective on Aflac from $102.00 to $103.00 and gave the stock an “equal weight” rating in a research report on Tuesday, May 6th. Barclays boosted their target price on Aflac from $95.00 to $96.00 and gave the stock an “underweight” rating in a research note on Thursday, May 1st. Finally, Raymond James lowered their price target on Aflac from $115.00 to $110.00 and set an “outperform” rating for the company in a report on Thursday, May 29th. Three investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Aflac presently has a consensus rating of “Hold” and an average target price of $104.93.

About Aflac

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.